menu
    • menu

    Company profile for Neutrolis

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Neutrolis, Inc. is a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cell in our body. Neutrolis’ lead program targets Neutrophil Extracellular Traps (NETs). NETs are a fundamental arm of the innate immune system and play an important role in chronic and acute diseases. Based in Cambridge, MA, Neutrolis was founded by two of the earliest and most cited leaders in the NETs fie...
    Neutrolis, Inc. is a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cell in our body. Neutrolis’ lead program targets Neutrophil Extracellular Traps (NETs). NETs are a fundamental arm of the innate immune system and play an important role in chronic and acute diseases. Based in Cambridge, MA, Neutrolis was founded by two of the earliest and most cited leaders in the NETs field and is supported by seasoned business leaders. The company’s pipeline includes NTR-441 and NTR-10 that effectively removes NETs and halt their pathologic effects.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NeutrolisUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    c/o LabCentral 700 Main Street, North Cambridge, MA 02139
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.neutrolis.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/neutrolis/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Neutrolis Names Caren Deardorf Chief Business & Strategy Officer
    Neutrolis Names Caren Deardorf Chief Business & Strategy Officer

    15 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/15/3274807/0/en/Neutrolis-Appoints-Caren-Deardorf-as-Chief-Business-Strategy-Officer.html

    GLOBENEWSWIRE
    15 Apr 2026
    Share Share
    Neutrolis Reports Positive Phase 1a Results for NTR-1011
    Neutrolis Reports Positive Phase 1a Results for NTR-1011

    02 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/02/3267224/0/en/Neutrolis-Announces-Positive-First-in-Human-Phase-1a-Results-from-LIBERATE-I-Trial-of-NTR-1011-a-First-in-Class-DNASE1L3-Fusion-Protein.html

    GLOBENEWSWIRE
    02 Apr 2026
    Share Share
    Neutrolis Appoints Mikael Dolsten As Executive Director On Board
    Neutrolis Appoints Mikael Dolsten As Executive Director On Board

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3242690/0/en/Neutrolis-Appoints-Mikael-Dolsten-M-D-Ph-D-to-Board-of-Directors-as-Executive-Director.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    Neutrolis Show 1st-in-Human Data on NET Clearance in Autoimmunity
    Neutrolis Show 1st-in-Human Data on NET Clearance in Autoimmunity

    29 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/29/3176704/0/en/Neutrolis-Presented-First-in-Human-Proof-of-Concept-Data-Validating-DNASE1L3-Mediated-Neutrophil-Extracellular-Trap-NET-Clearance-as-a-Therapeutic-Approach-in-Autoimmunity-at-Ameri.html

    GLOBENEWSWIRE
    29 Oct 2025
    Share Share
    Neutrolis Presents Clinical Results At Acr Convergence 2025
    Neutrolis Presents Clinical Results At Acr Convergence 2025

    13 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/13/3165746/0/en/Neutrolis-Announces-Late-Breaking-Oral-Presentation-of-Clinical-Results-at-American-College-of-Rheumatology-Convergence-2025.html

    GLOBENEWSWIRE
    13 Oct 2025
    Share Share
    Neutrolis Licenses UIC Patent for Dry Eye Disease Therapy
    Neutrolis Licenses UIC Patent for Dry Eye Disease Therapy

    23 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/23/3001191/0/en/Neutrolis-Licenses-University-of-Illinois-Chicago-Patent-to-Advance-Topical-Dry-Eye-Disease-Therapy-Targeting-NETs.html

    GLOBENEWSWIRE
    23 Dec 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search